MedTrace Logo

NovellusDx Tissue Collection Protocol

NCT01791322 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2018-03-29

No results posted yet for this study

Summary

NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.

Conditions

  • Patients That Have Been Diagnosed With Colorectal Cancer
  • Patients Eligible for Tumor Biopsy

Sponsors & Collaborators

  • Fore Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Yakov Felig, Dr. · Pathology lab Hadassah MC

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01791322 on ClinicalTrials.gov